date,title,source
Oct-26-18,Data from Clinical and Pre-Clinical Trials Evaluating Verona Pharmas RPL554 in Cystic Fibrosis Presented at North American Cystic Fibrosis Conference,GlobeNewswire
Oct-30-18,"Verona Pharma to Announce Interim Results for Nine Months Ended September 30, 2018 and Provide Clinical Development Update",GlobeNewswire
Oct-31-18,Verona Pharma Completes Enrollment in Phase 2 Clinical Trial Evaluating Nebulized RPL554 as Add-on to Dual Bronchodilator Therapy for COPD Maintenance Treatment,GlobeNewswire
Nov-06-18,"Verona Pharma plc Operational Update and Financial Results for the Three and Nine Months Ended September 30, 2018",GlobeNewswire
Dec-17-18,Verona Pharma Initiates Phase 2 Clinical Trial to Evaluate Dry Powder Inhaler Formulation of RPL554 for Maintenance Treatment of COPD,GlobeNewswire
Jan-03-19,"Verona Pharma Appoints Kathleen Rickard, MD, as Chief Medical Officer to Lead Late Stage Clinical Development of RPL554",GlobeNewswire
Jan-09-19,Verona Pharma Receives WHO Approval for ensifentrine as Recommended INN for RPL554,GlobeNewswire
Jan-11-19,Verona Pharma Sees Hammer Chart Pattern: Time to Buy?,Zacks
Jan-14-19,Verona Pharma Reports Encouraging Top-Line Data from Three-Day Phase 2 Trial Evaluating Nebulized Ensifentrine (RPL554) on Top of Dual Bronchodilator Therapy for COPD Maintenance Treatment,GlobeNewswire
Jan-16-19,Verona Pharma Enters Oversold Territory,Zacks
Feb-01-19,Verona Pharma Works Sees Hammer Chart Pattern: Time to Buy?,Zacks
Feb-04-19,Verona Pharma to Present at Upcoming Investor Conferences,GlobeNewswire
Feb-20-19,"Verona Pharma to Announce Financial Results for Full Year ended December 31, 2018 and Provide Clinical Development Update",GlobeNewswire
Feb-26-19,"Verona Pharma Reports Financial Results for Full Year Ended December 31, 2018 and Provides Clinical Development Update",GlobeNewswire
Feb-28-19,Verona Pharma to Present at Cowen and Company 39th Annual Health Care Conference,GlobeNewswire
Mar-04-19,Verona Pharma Reports Positive Interim Data with Ensifentrine Dry Powder Inhaler Formulation in First of Two-Part Phase 2 Clinical Trial in COPD,GlobeNewswire
Mar-05-19,PDMR Dealing,GlobeNewswire
Mar-07-19,PDMR Dealing,GlobeNewswire
Mar-11-19,PDMR Dealing,GlobeNewswire
Mar-20-19,PDMR Dealing,GlobeNewswire
Mar-21-19,Dr. Martin Edwards Joins Verona Pharma as Non-Executive Director,GlobeNewswire
Mar-25-19,PDMR Dealing,GlobeNewswire
Mar-26-19,Verona Pharma to Present at H.C. Wainwright Global Life Sciences Conference,GlobeNewswire
Apr-04-19,Grant of Options and RSUs and PDMR Dealings,GlobeNewswire
Apr-09-19,Verona Pharma Granted Key EU Patent Related to Late-stage COPD Clinical Candidate Ensifentrine,GlobeNewswire
May-01-19,"Verona Pharma to Announce Financial Results for First Quarter Ended March 31, 2019 and Provide Clinical Development Update",GlobeNewswire
May-02-19,Verona Pharma to Present Clinical Trial Data of Ensifentrine for COPD Maintenance Treatment at American Thoracic Society 2019 International Conference,GlobeNewswire
May-07-19,Result of AGM,GlobeNewswire
May-20-19,Verona Pharma Presents Expanded Analysis of Ensifentrine Clinical Data in COPD Maintenance Treatment at American Thoracic Society 2019 International Conference,GlobeNewswire
May-30-19,Verona Pharma to Present at Jefferies 2019 Global Healthcare Conference,GlobeNewswire
Jun-04-19,Verona Pharma Initiates Phase 2 Clinical Trial with Metered Dose Inhaler Formulation of Ensifentrine for Maintenance Treatment of COPD,GlobeNewswire
